Leah Phillips was just 43 years old when she was diagnosed with stage IV non-small-cell lung cancer (NSCLC) with an EGFR Exon-19 mutation. Despite her initial shock and a frustrating series of misdiagnoses, Leah’s determination and advocacy led to proper treatment.
Epidermal growth factor receptor (EGFR) exon 19 deletion (E19del) mutations are a type of in-frame deletion that occur in the kinase domain of the EGFR receptor. They are a common activating mutation in advanced non-small cell lung cancer (NSCLC) and are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs). E19del mutations account for about 60% of EGFR mutations associated with lung cancer and are made up of a heterogeneous group of variants.
Defying the Odds: A Survivor's Story
In her cancer vlog (YouTube
link), Leah recounts her journey from the first symptoms, through the relentless search for answers, to her current treatment with
Tagrisso. She shares how she balances life as a mother of three, the impact of her diagnosis, and her advice on the importance of seeking second opinions and being your own advocate.